(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of -7.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Enanta Pharmaceuticals's revenue in 2025 is $66,591,000.On average, 4 Wall Street analysts forecast ENTA's revenue for 2025 to be $1,340,153,079, with the lowest ENTA revenue forecast at $1,236,434,250, and the highest ENTA revenue forecast at $1,429,280,448. On average, 4 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,127,040,965, with the lowest ENTA revenue forecast at $704,187,277, and the highest ENTA revenue forecast at $1,427,147,194.
In 2027, ENTA is forecast to generate $1,149,184,145 in revenue, with the lowest revenue forecast at $667,921,953 and the highest revenue forecast at $1,557,275,712.